Last updated on March 2018

A Phase 2/3 Study Investigating The Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged Greater Than Or Equal To 6 Months to Less Than 6 Years With Severe Atopic Dermatitis


Brief description of study

The primary objective for part A of the study is to characterize the safety and pharmacokinetics (PK) of dupilumab administered as a single dose in pediatric patients, 6 months to less than 6 years of age with severe atopic dermatitis (AD).

The primary objective for part B of the study is to demonstrate the efficacy of multiple doses of dupilumab over 16 weeks of treatment when administered concomitantly with topical corticosteroids (TCS) in pediatric patients, 6 months to less than 6 years of age, with severe AD.

Clinical Study Identifier: TX201204

Contact Investigators or Research Sites near you

Start Over